EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC-ND 4.0

Lenvatinib plus pembrolizumab for advanced or recurrent endometrial cancer: A retrospective multi-institutional survey in the Kinki district of Japan

Yasushi Mabuchi, Kyoka Takahashi, Takuya Yokoe, Masato Kita, Shinichi Terada, Tomohito Tanaka, Masahide Ohmichi, Haruka Suzuki, Junzo Hamanishi, Masaki Mandai, Takuya Noda, Takeshi Fukuda und 19 weitere

Cancer Treatment and Research Communications · 2026

DOI: 10.1016/j.ctarc.2026.101157 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Cancer Treatment and Research Communications, 2026. Verfasst von Yasushi Mabuchi und 30 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Wakayama Medical University, Wakayama, Japan. Electronic address: booyan@wakayama-med.ac.jp. Hauptthemen laut MEDLINE: Endometrial Neoplasms, Antibodies, Monoclonal, Humanized, Quinolines, Phenylurea Compounds. Die Arbeit nennt 14 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Lenvatinib plus pembrolizumab therapy has recently attracted attention as a new treatment option. However limited information is currently available based on large-scale clinical experience in Japanese patients. The present study examined patients with advanced or recurrent endometrial cancer who were treated with lenvatinib and pembrolizumab in the Kinki district of Japan. METHODS: A total of 161 patients with advanced or recurrent endometrial cancer who received lenvatinib and pembrolizumab were enrolled from 13 hospitals in the Kinki district between December 2021 and July 2024. We retrospectively reviewed their medical records. RESULTS: In the overall patient population, median overall survival (OS) was 27 months and median progression-free survival (PFS) was 9 months. In patients with proficient mismatch repair (pMMR), median OS was 21 months and median PFS was 8 months. The cohort included 14 patients with carcinosarcoma, for whom median OS was 20 months and median PFS was 9 months. A univariate analysis showed that the histological subtype and MMR status correlated with PFS, while the histological subtype, MMR status, and platinum-free interval correlated with OS. A multivariate analysis identified age and the histological subtype as significant factors for PFS, while the histological subtype, MMR status, and platinum-free interval correlated with OS. CONCLUSION: The combination of lenvatinib and pembrolizumab showed favorable treatment outcomes for patients with advanced or recurrent endometrial cancer in the Kinki district. This regimen appeared to be more effective for patients with a longer platinum-free interval (>6 months), or endometrioid carcinoma, or deficient MMR.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Endometrial NeoplasmsAntibodies, Monoclonal, HumanizedQuinolinesPhenylurea CompoundsNeoplasm Recurrence, LocalAntineoplastic Combined Chemotherapy ProtocolsHumansFemaleRetrospective StudiesJapanAgedMiddle AgedAged, 80 and overProgression-Free Survival

Stichwörter der Autor:innen

Endometrial cancerImmune checkpoint inhibitorLenvatinibMultikinase inhibitorPembrolizumab

Substanzen

lenvatinibAntibodies, Monoclonal, HumanizedQuinolinespembrolizumabPhenylurea Compounds

Autor:innen und Institutionen

  • Department of Obstetrics and Gynecology, Wakayama Medical University, Wakayama, Japan. Electronic address: booyan@wakayama-med.ac.jp.
  • Department of Obstetrics and Gynecology, Wakayama Medical University, Wakayama, Japan.
  • Department of Obstetrics and Gynecology, Kansai Medical University, Hirakata, Osaka, Japan.
  • Department of Obstetrics and Gynecology, Osaka Medical and Pharmaceutical University, Takatsuki, Osaka, Japan.
  • Department of Gynecology and Obstetrics, Graduate School of Medicine, Kyoto University, Kyoto, Japan; Department of Gynecology and Obstetrics, Mitsubishi Kyoto Hospital, Kyoto, Japan.
  • Department of Gynecology and Obstetrics, Graduate School of Medicine, Kyoto University, Kyoto, Japan; Department of Obstetrics and Gynecology, National Hospital Organization, Kyoto Medical Center, Kyoto, Japan.

Zitieren

APA

Mabuchi, Y., Takahashi, K., Yokoe, T., Kita, M., Terada, S., Tanaka, T., Ohmichi, M., Suzuki, H., Hamanishi, J., Mandai, M., Noda, T., Fukuda, T., Sumi, T., Kashima, Y., Nakai, H., Matsumura, N., Yoneoka, Y., Amano, T., Matsumoto, M., …, & Ino, K. (2026). Lenvatinib plus pembrolizumab for advanced or recurrent endometrial cancer: A retrospective multi-institutional survey in the Kinki district of Japan. Cancer Treatment and Research Communications. https://doi.org/10.1016/j.ctarc.2026.101157

Vancouver

Mabuchi Y, Takahashi K, Yokoe T, Kita M, Terada S, Tanaka T, et al. Lenvatinib plus pembrolizumab for advanced or recurrent endometrial cancer: A retrospective multi-institutional survey in the Kinki district of Japan. Cancer Treatment and Research Communications. 2026. doi:10.1016/j.ctarc.2026.101157

BibTeX
@article{Mabuchi2026,
  author = {Mabuchi, Yasushi and Takahashi, Kyoka and Yokoe, Takuya and Kita, Masato and Terada, Shinichi and Tanaka, Tomohito and Ohmichi, Masahide and Suzuki, Haruka and Hamanishi, Junzo and Mandai, Masaki and Noda, Takuya and Fukuda, Takeshi and Sumi, Toshiyuki and Kashima, Yoko and Nakai, Hidekatsu and Matsumura, Noriomi and Yoneoka, Yutaka and Amano, Tsukuru and Matsumoto, Mariko and Okubo, Tomoharu and Okamura, Ayaka and Mori, Taisuke and Nakatani, Sayaka and Akada, Shinobu and Kojima, Machiko and Horie, Akihito and Ogura, Eri and Tatsumi, Keiji and Matsuoka, Motoki and Kawaguchi, Ryuji and Ino, Kazuhiko},
  title = {Lenvatinib plus pembrolizumab for advanced or recurrent endometrial cancer: A retrospective multi-institutional survey in the Kinki district of Japan},
  journal = {Cancer Treatment and Research Communications},
  year = {2026},
  doi = {10.1016/j.ctarc.2026.101157}
}
Kostenlos starten →